These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17855727)

  • 61. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
    Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
    Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection.
    Rivard RG; McCall S; Griffith ME; Hawley JS; Ressner RA; Borra H; Moon JE; Beckius ML; Murray CK; Hospenthal DR
    Med Mycol; 2007 Dec; 45(8):685-9. PubMed ID: 17885951
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.
    Najvar LK; Cacciapuoti A; Hernandez S; Halpern J; Bocanegra R; Gurnani M; Menzel F; Loebenberg D; Graybill JR
    Antimicrob Agents Chemother; 2004 Mar; 48(3):758-64. PubMed ID: 14982761
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
    Ibrahim AS; Gebremariam T; Schwartz JA; Edwards JE; Spellberg B
    Antimicrob Agents Chemother; 2009 Feb; 53(2):772-5. PubMed ID: 18936190
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
    Olson JA; George A; Constable D; Smith P; Proffitt RT; Adler-Moore JP
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3884-94. PubMed ID: 20606065
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
    Felton TW; Baxter C; Moore CB; Roberts SA; Hope WW; Denning DW
    Clin Infect Dis; 2010 Dec; 51(12):1383-91. PubMed ID: 21054179
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection.
    Ruíz-Cendoya M; Madrid H; Pastor J; Guarro J
    Int J Antimicrob Agents; 2010 Feb; 35(2):152-5. PubMed ID: 20005680
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.
    Barchiesi F; Spreghini E; Schimizzi AM; Maracci M; Giannini D; Carle F; Scalise G
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3312-6. PubMed ID: 15328090
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Fulminant invasive fungal sinusitis in immunosuppressed hosts -- pathognomic presentation in MRI].
    Hahn U; Lengerke A; Küker W
    Rofo; 2004 May; 176(5):758-60. PubMed ID: 15122477
    [No Abstract]   [Full Text] [Related]  

  • 70. Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice.
    Palicz Z; Gáll T; Leiter É; Kollár S; Kovács I; Miszti-Blasius K; Pócsi I; Csernoch L; Szentesi P
    Emerg Microbes Infect; 2016 Nov; 5(11):e114. PubMed ID: 27826143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response.
    Becker MJ; de Marie S; Fens MH; Hop WC; Verbrugh HA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2002 May; 49(5):813-20. PubMed ID: 12003976
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
    Barchiesi F; Santinelli A; Biscotti T; Greganti G; Giannini D; Manso E
    J Antimicrob Chemother; 2016 Aug; 71(8):2230-3. PubMed ID: 27231274
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
    Lepak AJ; Marchillo K; Vanhecker J; Andes DR
    Antimicrob Agents Chemother; 2013 Jan; 57(1):579-85. PubMed ID: 23147740
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.
    Meletiadis J; Petraitis V; Petraitiene R; Lin P; Stergiopoulou T; Kelaher AM; Sein T; Schaufele RL; Bacher J; Walsh TJ
    J Infect Dis; 2006 Oct; 194(7):1008-18. PubMed ID: 16960790
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
    Gavaldà J; Martín MT; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruíz I; Pahissa A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3028-30. PubMed ID: 15980392
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
    Hope WW; Kruhlak MJ; Lyman CA; Petraitiene R; Petraitis V; Francesconi A; Kasai M; Mickiene D; Sein T; Peter J; Kelaher AM; Hughes JE; Cotton MP; Cotten CJ; Bacher J; Tripathi S; Bermudez L; Maugel TK; Zerfas PM; Wingard JR; Drusano GL; Walsh TJ
    J Infect Dis; 2007 Feb; 195(3):455-66. PubMed ID: 17205486
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment and developmental therapeutics in aspergillosis. 1. Amphotericin B and its derivatives.
    Georgiev VS
    Respiration; 1992; 59(5):291-302. PubMed ID: 1488564
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.
    McCulloch E; Ramage G; Rajendran R; Lappin DF; Jones B; Warn P; Shrief R; Kirkpatrick WR; Patterson TF; Williams C
    J Clin Pathol; 2012 Jan; 65(1):83-6. PubMed ID: 22049217
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Treatment of experimental invasive pulmonary aspergillosis in rats with liposomal amphotericin B].
    Matsuda H; Kohno S; Miyazaki Y; Mitsutake K; Tanaka K; Maesaki S; Iwamoto M; Hashimoto A; Kaku M; Koga H
    Kansenshogaku Zasshi; 1993 Feb; 67(2):102-9. PubMed ID: 8468494
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of intranasally dosed posaconazole on fungal load and biomarkers in Aspergillus fumigatus infected immunocompromised mice.
    Kimura G; Nakaoki T; Nishimoto Y; Suzuki Y; Rapeport G; Strong P; Ito K; Kizawa Y
    Mycoses; 2017 Nov; 60(11):728-735. PubMed ID: 28699245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.